---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016046"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T02:08:52.143827+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vir Q2 net loss $76.5M; revenue negative on $397.4M non-cash charge; >$2.6B cash

## Summary
- Net loss of $76.5M ($0.58 per share) vs net income of $61.8M ($0.48) in Q2 2021.
- Total revenue negative ($40.6M) due to $397.4M non-cash charge for excess sotrovimab supply and manufacturing capacity.
- Collaboration revenue from GSK was ($54.9M); $342.5M profit-share expected in Q3 2022.
- Cash, equivalents, investments and profit-share payments exceed $2.6B, expected to fund operations for up to five years.
- HERBERT 'SKIP' VIRGIN, CSO, stepping down Aug 30; CMO Phil Pang to lead R&D on interim basis.

## SEC filing metadata
- accession: 0000950170-22-016046
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000095017022016046/0000950170-22-016046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000095017022016046/vir-20220809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016046
- JSON: https://secwatch.observer/filing/0000950170-22-016046.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.